Kuvatris Therapeutics Inc's ROI from its third quarter of 2024 to the third quarter of 2023 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Kuvatris Therapeutics Inc's ROI in the third quarter of 2024?
Kuvatris Therapeutics Inc recorded a cumulative net loss of $-14 million during 12 months ending in the third quarter of 2024, resulting in a negative return on investment (ROI) of -1909.96%.

Within the Healthcare sector 925 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the second quarter of 2024 from 4411 to 4754.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Sep 30 2024) III. Quarter	(Jun 30 2024) II. Quarter	(Mar 31 2024) I. Quarter	(Dec 31 2023) IV. Quarter	(Sep 30 2023) III. Quarter
Y / Y Investment Change TTM	-50.63 %	-48.21 %	-	-	-
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	-1	-1	2	4	0
Return On Investment (TTM)	-	-	-879.19 %	-768.46 %	-
PXMD's Overall Ranking	# 4754	# 4411	# 3207	# 3453	# 3774
Seq. Investment Change TTM	-32.97 %	-48.76 %	-13.27 %	65.74 %	-29.69 %
Seq. Net Income Change TTM	-	-	-	-	-
Net Income (TTM) in Millions	-14	-18	-18	-18	-12

PXMD Company Profile >> Back to PXMD Roi Comparisons >> See Annual PXMD Return On Investment

Return On Investment PXMD's Ranking
Within:	No.
Industry	# 461
Sector	# 926
Overall	# 4754

Return On Investment Statistics
High	Average	Low
-768.46 %	-1168.35 %	-1909.96 %
(Dec 31 2023)		(Sep 30 2024)

Financial Statements
Kuvatris Therapeutics Inc's III. Quarter Investments	$ -1 Millions	PXMD's Balance sheet
Kuvatris Therapeutics Inc's III. Quarter Income	$ -1 Millions	Quarterly PXMD's Income Statement
PXMD's Income by Division		See PXMD's Income by Division

PXMD Annual Return On Investment	(Dec 31 2023) 2023	(Dec 31 2022) 2022
Total Investments in Millions	4	0	0	0	0
Y / Y Investment Growth	3470.28 %	-	-	-	-
Net Income in Millions	-18	-15	0	0	0
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-470.77 %	-13602.31 %	-	-	-

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
PXMD's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for PXMD's Competitors
Subscribers only: Roi for Kuvatris Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for PXMD's Customers

Other Ratios
PXMD's Roa	PXMD's Inventory Turnover Ratio	PXMD's Growth Rates	PXMD's Dividend Statistics
	PXMD's Profitability Ratios	PXMD's Asset Turnover Ratio	PXMD's Dividend Growth
PXMD's Roe	PXMD's Valuation Ratios	PXMD's Financial Strength Ratios	PXMD's Dividend Payout Ratio

Companies with similar Return On Investment at Sep 30 2024, within Healthcare Sector

ROI

Date modified: 2026-06-22T14:32:45+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.